05/27/2021 10:40 AM
Clarín.com
Society
Updated 05/27/2021 10:47 AM
The US Food and Drug Administration (FDA) granted an emergency use authorization for
sotrovimab
, an investigational single-dose monoclonal antibody, for the treatment of mild to moderate coronavirus in adults and pediatric patients (12 and older). years and weighing at least 40 kg) who are at high risk of progression to serious condition.
"With the authorization of this monoclonal antibody treatment, we are providing another option to help keep high-risk COVID-19 patients
out of the hospital,
" said Patrizia Cavazzoni, MD, director of the Center for Drug Evaluation and Research at the FDA.
"It is important to expand the arsenal of monoclonal antibody therapies that are expected to retain activity against circulating covid-19 variants in the United States," added Cavazzoni.
News in development.
LGP